Page last updated: 2024-09-05

campesterol and alpha-Lipoprotein Deficiency Disease, Familial

campesterol has been researched along with alpha-Lipoprotein Deficiency Disease, Familial in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bentley, D; Kallend, D; Kastelein, JJ; Kees Hovingh, G; Niesor, EJ; Stroes, ES	1

Trials

1 trial(s) available for campesterol and alpha-Lipoprotein Deficiency Disease, Familial

Article	Year
Treatment of low HDL-C subjects with the CETP modulator dalcetrapib increases plasma campesterol only in those without ABCA1 and/or ApoA1 mutations. Lipids, 2014, Volume: 49, Issue:12 Topics: Amides; Apolipoprotein A-I; ATP Binding Cassette Transporter 1; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cross-Over Studies; Double-Blind Method; Esters; Humans; Hypoalphalipoproteinemias; Mutation; Phytosterols; Sulfhydryl Compounds; Treatment Outcome	2014

Article

Year

Treatment of low HDL-C subjects with the CETP modulator dalcetrapib increases plasma campesterol only in those without ABCA1 and/or ApoA1 mutations.

Lipids, 2014, Volume: 49, Issue:12

Topics: Amides; Apolipoprotein A-I; ATP Binding Cassette Transporter 1; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cross-Over Studies; Double-Blind Method; Esters; Humans; Hypoalphalipoproteinemias; Mutation; Phytosterols; Sulfhydryl Compounds; Treatment Outcome

2014